D. Boral Capital Facilitates $22 Million Offering for Omeros Corporation, Signaling Biopharmaceutical Sector Confidence

D. Boral Capital LLC, a New York-based global investment bank, recently acted as the exclusive placement agent for Omeros Corporation in a registered direct offering that raised approximately $22 million. The transaction, which closed on July 28, 2025, involved the sale of 5,365,853 shares of common stock at $4.10 per share, a price that marked a 14% premium to the closing price on the date of the securities purchase agreement, July 24, 2025. This premium pricing is significant because it indicates strong investor confidence in Omeros's future prospects, suggesting that market participants are willing to pay above-market rates to participate in the company's growth trajectory. The offering was conducted under a 'shelf' Registration Statement on Form S-3 and the accompanying prospectus, showcasing the strategic financial maneuvers Omeros Corporation is undertaking to bolster its position in the biopharmaceutical sector.

The involvement of Polar Asset Management Partners as a key investor underscores the confidence in Omeros's potential and the strategic importance of this capital infusion. This matters because institutional investors like Polar Asset Management Partners typically conduct thorough due diligence before committing funds, and their participation signals a vote of confidence in Omeros's research pipeline and management team. D. Boral Capital LLC's expertise in navigating complex financial landscapes is evident in this transaction, further cementing its reputation as a premier investment bank for middle-market and emerging growth companies. With a track record of aggregating approximately $30 billion in capital since its inception in 2020, the firm continues to demonstrate its ability to deliver tailored financial solutions across diverse sectors worldwide. For more information on D. Boral Capital LLC, visit https://dboralcapital.com/.

The successful closure of this offering not only provides Omeros Corporation with the necessary funds to advance its research and development initiatives but also highlights the growing investor interest in the biopharmaceutical industry. This is important because the biopharmaceutical sector requires substantial capital for drug development, clinical trials, and regulatory approvals, and successful fundraising enables companies like Omeros to pursue innovative treatments without compromising their operational stability. The transaction is a testament to the robust financial strategies employed by companies like Omeros to navigate the challenges of drug development and commercialization in a highly competitive market. The implications extend beyond Omeros itself, as it reflects broader trends in healthcare investment where investors are increasingly backing companies with promising therapeutic pipelines, potentially accelerating medical advancements and addressing unmet patient needs. This capital raise positions Omeros to potentially accelerate its clinical programs, enhance its competitive edge, and contribute to the dynamic biopharmaceutical ecosystem centered in the New York metro area and beyond.